Senior in-house counsel share candid views on AI tools, governance frameworks and the urgent need for privacy law reform in Canada
Health legal leaders on AI governance, cybersecurity and legal reform
Teva and Samsung Bioepis Add Up to Six Biosimilar Candidates to Partnership
On October 1, 2026, Teva Pharmaceutical Industries Ltd. (“Teva”) and Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) announced a new global license, development, and commercialization agreement for up to six potential biosimilar candidates. As with the companies’ previous collaborations, Samsung Bioepis
Firm Attorneys Appear in DRI’s For the Defense Magazine
Three members of the firm’s Medical and Life Sciences Practice Group recently wrote a column examining the scope of OTC preemption and a shift toward defense-favorable decisions that was published in a magazine targeting defense, insurance and corporate counsel.
Firm Partner Discusses L’Oréal Acne Products Court Decision with Media
Harris Beach Murtha Partner Kelly Jones Howell recently spoke with Chemical Watch News & Insight for a story about a recent federal court in New York dismissing multi-district litigation (MDL) alleging certain benzoyl peroxide (BPO) acne products produced by L’Oréal
What Providers Should Consider Before Moving to Concierge Medicine
Concierge medicine is attracting growing attention for both providers reconsidering how they practice and patients reconsidering how they choose to receive medical care. Membership-based models offer the prospect of smaller patient panels, more time with patients, less complex compensation models,
FDA Finalizes Q&A Guidance on Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products
On October 13, 2026, the FDA announced the availability of a final guidance for industry entitled “Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers,” finalizing a previously issued draft guidance of the same title issued on
One Front Door: DOJ Takes Over Healthcare Fraud Self-Disclosure
Publications
cridge
Mon, 10/19/2026 – 12:51
Featured
On
Alert Type
Litigation Alert
Include Disclaimer
On
Date
10.19.2026
Description
On October 15, 2026, the Department of Justice’s (DOJ) National Fraud Enforcement Division (Fraud Division) and the Department of Health and Human
TEFCA Sets October 26 Compliance Deadline for IAS as Federal Oversight Expands
TEFCA’s Qualified Health Information Networks (QHINs) have a deadline coming up fast: 5:00 p.m. Eastern on October 26, 2026. In its October 13 compliance bulletin, The Sequoia Project issued interim technical directions for Individual Access Services (IAS), which support
Shared Savings, Surprise Bills, and Your TPA: What Kreutzmann v. Cigna Means for Self-Funded Group Health Plan Fiduciaries
A newly filed class action against Cigna Health and Life Insurance Company puts a spotlight on a common but often overlooked feature of administrative services only (ASO) agreements: “shared savings” fees that pay the third-party administrator (TPA) a percentage of
Healthcare & Life Sciences Private Equity Deal Tracker: Amulet Recaps US Fertility
Amulet Capital Partners recently announced the closing of a recapitalization of US Fertility through a new continuation vehicle.
US Fertility, founded in 2020 and based in Rockville, Maryland, is a fertility services platform.
Amulet, founded in 2015 and